- Home
- DSL vs XERS Comparison
DSL vs XERS Comparison
Compare DSL & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSL | XERS |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | DSL | XERS |
|---|---|---|
| Price | $11.16 | $7.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.43 |
| AVG Volume (30 Days) | 784.6K | ★ 2.1M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 11.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $266,137,000.00 |
| Revenue This Year | N/A | $44.37 |
| Revenue Next Year | N/A | $27.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 42.05 |
| 52 Week Low | $10.58 | $3.14 |
| 52 Week High | $12.92 | $10.08 |
Technical Indicators
Market Signals| Indicator | DSL | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 34.50 | 49.66 |
| Support Level | $11.12 | $6.97 |
| Resistance Level | $11.23 | $7.45 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 22.22 | 76.92 |
Price Performance
Historical ComparisonAbout DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).